Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo.
J Exp Med
; 218(3)2021 03 01.
Artículo
en Inglés
| MEDLINE | ID: covidwho-1044017
ABSTRACT
SARS-CoV-2, the causative agent of COVID-19, has been responsible for over 42 million infections and 1 million deaths since its emergence in December 2019. There are few therapeutic options and no approved vaccines. Here, we examine the properties of highly potent human monoclonal antibodies (hu-mAbs) in a Syrian hamster model of SARS-CoV-2 and in a mouse-adapted model of SARS-CoV-2 infection (SARS-CoV-2 MA). Antibody combinations were effective for prevention and in therapy when administered early. However, in vitro antibody neutralization potency did not uniformly correlate with in vivo protection, and some hu-mAbs were more protective in combination in vivo. Analysis of antibody Fc regions revealed that binding to activating Fc receptors contributes to optimal protection against SARS-CoV-2 MA. The data indicate that intact effector function can affect hu-mAb protective activity and that in vivo testing is required to establish optimal hu-mAb combinations for COVID-19 prevention.
Texto completo:
Disponible
Colección:
Bases de datos internacionales
Base de datos:
MEDLINE
Asunto principal:
Neumonía Viral
/
Infecciones por Coronavirus
/
Anticuerpos Neutralizantes
/
Anticuerpos Monoclonales de Origen Murino
/
Pandemias
/
Betacoronavirus
/
Anticuerpos Antivirales
Tipo de estudio:
Estudio experimental
Tópicos:
Vacunas
Límite:
Animales
/
Femenino
/
Humanos
Idioma:
Inglés
Año:
2021
Tipo del documento:
Artículo
País de afiliación:
JEM.20201993
Similares
MEDLINE
...
LILACS
LIS